Menu
Search
Home > Courses > HIV Treatment in an Era of Polypharmacy: The Current and Future Challenges with Drug Interactions

HIV Treatment in an Era of Polypharmacy: The Current and Future Challenges with Drug Interactions

HIV Treatment in an Era of Polypharmacy: The Current and Future Challenges with Drug Interactions
Play
Sorry, this learning module is not available for mobile devices.
Original Release Date: 8/20/2019
Termination Date: 08/19/2022
Review Date: 10/21/2019
Presenter
  • David J. Back, PhD
    Professor of Molecular and Clinical Pharmacology
    Institute of Translational Medicine, University of Liverpool, UK
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Be aware of the increasing burden and complexity of multi-morbidity and polypharmacy in older HIV patients.
  2. Know about the basic mechanisms of drug-drug interactions and the inclusion of interaction data in the label.
  3. Appreciate the different interaction potential of antiretrovirals in our current guidelines and have a clear understanding of which interactions should always be on our radar!
  4. Have some understanding as to whether in the long acting era drug interactions will still be of concern!
Presenter Bio
David Back, PhD
David Back is a Professor of Pharmacology at the University of Liverpool and has worked in the area of Pharmacokinetics and drug –drug interactions for more than 35 years. He established the Liverpool HIV Pharmacology Group (LHPG) in 1987 and subsequently the Liverpool group has been at the forefront of pharmacological research of anti-infective drugs, specifically for HIV and HCV. Currently there are numerous ongoing pharmacokinetic, pharmacogenetic and molecular-based studies involving local, national and international collaborations. David has authored ~400 publications. He is a former Editor in chief of the British Journal of Clinical Pharmacology and is on the Editorial Board of numerous journals. He has established several key resources for health care professionals including www.hiv-druginteractions.org and www.hep-druginteractions.org. In 2007 he was awarded the Lilly Prize from the British Pharmacological Society for outstanding contribution to Clinical Pharmacology.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit on August 20, 2019 and will terminate August 19, 2022.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

 Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. David Back, PHD (Presenter) has no relevant financial relationships to disclose. Dr. Back submitted his slides in advance for adequate peer review, and will support his  presentation and clinical recommendations with the best available evidence from the medical literature.

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Gilead Sciences, Janssen Therapeutics (a division of Janssen Products, LP), Merck & Co., and ViiV Healthcare.

Details: 

  • This online video and post-activity evaluation are one hour in length. 
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules